Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Complex regional pain syndrome and dysautonomia in a 14-year-old girl responsive to therapeutic plasma exchange.

Hendrickson JE, Hendrickson ET, Gehrie EA, Sidhu D, Wallukat G, Schimke I, Tormey CA.

J Clin Apher. 2016 Aug;31(4):368-74. doi: 10.1002/jca.21407. Epub 2015 May 23.

PMID:
26011726
2.

[Rituximab (anti-CD20) in neurological disorders].

Akaishi T, Nakashima I.

Brain Nerve. 2014 Oct;66(10):1167-78. doi: 10.11477/mf.1416200006. Japanese.

PMID:
25296871
3.

[Favourable outcome after treatment with rituximab in a case of seronegative non-paraneoplastic Lambert-Eaton myasthenic syndrome].

Boutin E, Rey C, Romeu M, Pouget J, Franques J.

Rev Med Interne. 2013 Aug;34(8):493-6. doi: 10.1016/j.revmed.2013.04.007. Epub 2013 Jun 4. French.

PMID:
23759215
4.

Treatment options in paraneoplastic disorders of the peripheral nervous system.

Antoine JC, Camdessanché JP.

Curr Treat Options Neurol. 2013 Apr;15(2):210-23. doi: 10.1007/s11940-012-0210-9.

PMID:
23307613
5.

Treatment in Lambert-Eaton myasthenic syndrome.

Maddison P.

Ann N Y Acad Sci. 2012 Dec;1275:78-84. doi: 10.1111/j.1749-6632.2012.06769.x. Review.

PMID:
23278581
6.

Paraneoplastic syndromes of the neuromuscular junction: therapeutic options in myasthenia gravis, lambert-eaton myasthenic syndrome, and neuromyotonia.

van Sonderen A, Wirtz PW, Verschuuren JJ, Titulaer MJ.

Curr Treat Options Neurol. 2013 Apr;15(2):224-39. doi: 10.1007/s11940-012-0213-6.

PMID:
23263888
7.

A novel approach to paraneoplastic intestinal pseudo-obstruction.

Badari A, Farolino D, Nasser E, Mehboob S, Crossland D.

Support Care Cancer. 2012 Feb;20(2):425-8. doi: 10.1007/s00520-011-1305-7. Epub 2011 Nov 10.

PMID:
22072051
8.

[Monoclonal antibodies in inflammatory disease of the muscle and peripheral nervous system].

Aldea JJ.

Neurologia. 2012 Jan;27(1):39-45. doi: 10.1016/j.nrl.2011.02.005. Epub 2011 Apr 8. Review. Spanish.

9.

A review: the use of rituximab in neuromuscular diseases.

Ibrahim H, Dimachkie MM, Shaibani A.

J Clin Neuromuscul Dis. 2010 Dec;12(2):91-102. doi: 10.1097/CND.0b013e3181ff49f3. Review.

PMID:
21386778
10.

Autoimmune mediated neuromuscular junction defects.

Farrugia ME, Vincent A.

Curr Opin Neurol. 2010 Oct;23(5):489-95. doi: 10.1097/WCO.0b013e32833cc968. Review.

PMID:
20651592
11.

The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome.

Maddison P, McConville J, Farrugia ME, Davies N, Rose M, Norwood F, Jungbluth H, Robb S, Hilton-Jones D.

J Neurol Neurosurg Psychiatry. 2011 Jun;82(6):671-3. doi: 10.1136/jnnp.2009.197632. Epub 2010 Apr 14.

PMID:
20392977
12.

Favorable response to rituximab in a patient with anti-VGCC-positive Lambert-Eaton myasthenic syndrome and cerebellar dysfunction.

Pellkofer HL, Voltz R, Kuempfel T.

Muscle Nerve. 2009 Aug;40(2):305-8. doi: 10.1002/mus.21315.

PMID:
19609921
13.

[Myasthenia gravis].

Fleury MC, Tranchant C.

Rev Prat. 2008 Dec 31;58(20):2217-24. Review. French.

PMID:
19209651
14.

Neuromuscular diseases.

Kelly JJ.

Rev Neurol Dis. 2008 Winter;5(1):23-6. No abstract available.

PMID:
18418319
15.

Paraneoplastic syndromes in neuro-ophthalmology.

Alabduljalil T, Behbehani R.

Curr Opin Ophthalmol. 2007 Nov;18(6):463-9. Review.

PMID:
18162997

Supplemental Content

Loading ...
Support Center